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In this prospective clinical study, the safety and efﬁcacy of preemptive interferon-a (IFN-a) treatment were
investigated and compared with preemptive donor lymphocyte infusion (DLI) in patients who were minimal
residual disease (MRD)-positive after allogeneic hematopoietic stem cell transplantation (HSCT). Patients
undergoing allogeneic HSCT were eligible if they had acute leukemia or myelodysplastic syndrome and were
MRD-positive after HSCT. Patients who were able to receive DLI were assigned to a preemptive DLI group (n ¼
45); patients who could not or did not agree to receive DLI after HSCT received preemptive IFN-a. A total of 22
patients received preemptive IFN-a; the median treatment duration was 35 days (range, 4 to 180 days). Seven
patients relapsed, and 1 patient died from severe pneumonia. The 1-year cumulative incidence of chronic
graft-versus-host disease (cGVHD) after intervention was 90.9% for the IFN-a group and 62.9% for the DLI
group (P < .001). MRD status after preemptive intervention was comparable in the 2 groups, and the 1-year
cumulative incidence of relapse after intervention was 27.3% for the IFN-a group and 35.6% for the DLI group
(P ¼ .514). The 1-year cumulative incidence of nonrelapse mortality after intervention was 4.5% for the IFN-a
group and 4.4% for the DLI group (P ¼ .985). The 1-year probability of disease-free survival after intervention
was 68.2% for the IFN-a group and 60.0% for the DLI group (P ¼ .517). In multivariate analysis, early-onset
MRD, persistent MRD after intervention, and absence of cGVHD after intervention were signiﬁcantly asso-
ciated with poorer clinical outcomes. Thus, preemptive IFN-amay be a potential alternative for MRD-positive
patients who cannot receive preemptive DLI after HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION patients with advanced-stage acute leukemia receiving
Allogeneic hematopoietic stem cell transplantation
(HSCT) is one of the most effective treatments for hemato-
logic malignancies. Although HSCT has advanced signiﬁ-
cantly, post-transplantation relapse remains a major cause of
transplant failure, and further therapeutic options are
limited [1]. Prophylactic donor lymphocyte infusion (DLI) is
one of the most effective methods for relapse prophylaxis indgments on page 1946.
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ty for Blood and Marrow Transplantation.allogeneic HSCT [2-5]. In addition, because impending
relapse can be indicated by minimal residual disease (MRD)
after HSCT, preemptive intervention with DLI based on MRD
status may be a more reasonable option for relapse pro-
phylaxis after HSCT. Previous studies observed that clinical
outcomes of MRD-positive patients receiving preemptive DLI
were comparable to those of MRD-negative patients, and
signiﬁcantly better than those of MRD-positive patients who
received no interventions [6,7].
Some patients cannot receive DLI because of provider
refusal, however, and some patients themselves refuse DLI
after HSCT. For these patients, further study into reasonable
alternative preemptive interventions is needed. Interferon-a
X.-D. Mo et al. / Biol Blood Marrow Transplant 21 (2015) 1939e19471940(IFN-a) exerts a relatively strong immunomodulatory effect
and can kill acute myelogenous leukemia (AML) cells by
regulating T cell and natural killer cell functions [8,9]. It is
possible that IFN-a can induce a graft-versus-leukemia (GVL)
effect and clear tumor cells in patients after HSCT. This GVL-
promoting activity was ﬁrst observed during treatment of
patients with relapsed chronic myelogenous leukemia
[10,11]. Singhal et al. [12] also reported a patient with
relapsed AML who developed limited chronic graft-versus-
host disease (cGVHD) at 4 months after IFN-a therapy. At
the same time, the number of bone marrow (BM) blasts
decreased from 16% to 1% to 6%. Gesundheit et al. [13]
reported a patient with AML who experienced post-
transplantation relapse who received 2 doses of IFN-a at 18
days after DLI. GVHD was induced immediately, and the
patient remained in complete remission (CR) for 2 years after
the IFN-a treatment. In addition, several studies have sug-
gested that immunotherapy preferably should be started in
patients with leukemia with a relatively low tumor burden
[9], and our pilot study also observed that IFN-a could help
clear MRD after HSCT [14]. Thus, IFN-a may be a potentially
alternative treatment for MRD-positive patients after allo-
geneic HSCT.
In this prospective study, the safety and efﬁcacy of pre-
emptive IFN-awere investigated and comparedwith those of
preemptive DLI in patients who were MRD-positive after
undergoing allogeneic HSCT.PATIENTS AND METHODS
Patients
A total of 465 consecutive patients with acute leukemia in ﬁrst or second
CR [without t(9;22) mutation] or myelodysplastic syndrome-refractory
anemia with excess blasts underwent non-T cell-depleted allogeneic HSCT
at the Peking University Institute of Hematology (PUIH) between May 1,
2012, and January 1, 2014. A total of 365 subjects were MRD-negative at all
time points tested after HSCT. One hundred subjects were MRD-positive;
those who were able to receive DLI were assigned to a preemptive DLI
group, and those who could not receive DLI or who refused DLI after HSCT
were assigned to the IFN-a group. Patients who received DLI after IFN-a
treatment (n ¼ 3) or received IFN-a treatment after DLI (n ¼ 4) were
excluded from the analysis. A total of 67 patients were enrolled, including 22
in the preemptive IFN-a group and 45 in the preemptive DLI group (Figure 1
and Table 1). Twenty-six patients wereMRD-positive but did not receive any
preemptive intervention because of active GVHD (n ¼ 13) or active infection
(n ¼ 12), and 1 patient received only tapered immunosuppressive therapy.Figure 1. Diagram of preemptive intervention strategy based on MRD status. The p
included in the MRD-positive without intervention group.The ﬁnal follow-up visits for endpoint analysis were conducted in January
2015. To further compare the clinical outcomes between MRD-positive pa-
tients with and without preemptive intervention, a historical cohort
(including MRD-positive patients without intervention) that had been re-
ported by Zhao et al. [15] was enrolled as well (n ¼ 14). Informed consent
was obtained from all patients, and the study was conducted in accordance
with the Declaration of Helsinki. The study protocol was approved by the
Ethics Committee of Peking University People’s Hospital.
Transplantation Regimens
Preconditioning consisted of cytarabine (Ara-C), busulfan (4
mg$kg1$day1 administered orally on days8 to 6 before January 2008 or
3.2 mg$kg1$day1 administered i.v. on days 8 to 6 after January 2008),
cyclophosphamide (1.8 g$m2$day1 on days 5 to 4), and simustine (250
mg$m2 on day 3). Ara-C was administered at 4 g$m2$day1 on days 10
to 9 in the HLA-haploidentical related donor (haplo-RD) group and 2
g$m2$day1 on day9 in the HLA-identical sibling donor (ISD) group; rabbit
antithymocyte globulin (2.5 mg/kg on days 5 to 2; Thymoglobulin, Sanoﬁ,
Gentilly, France)was administered in the haplo-RD group [16,17]. Granulocyte
colony-stimulating factor (G-CSF)-mobilized, fresh, and unmanipulated BM
and peripheral blood harvests were infused into recipients on the day of
collection. In addition, patients received cyclosporine A (CSA), mycophenolate
mofetil, and short-term methotrexate (MTX) as graft-versus-host disease
(GVHD) prophylaxis [18]. Comorbidities in HSCT recipients were assessed
based on the hematopoietic cell transplantation-speciﬁc comorbidity index
(HCT-CI) [19]. Donor selection, HLA typing, and stem cell harvesting have
been described in detail previously [20].
MRD Monitoring and Deﬁnition
Patients were monitored for MRD post-transplantation according to
leukemia-associated aberrant immune phenotypes (LAIPs) and genes. LAIPs
were detected by 4-color ﬂow cytometry (FCM) (FACSCalibur; BD Bio-
sciences, San Jose, CA). FCM positivity was deﬁned as>0.01% of cells with an
LAIP in post-transplantation BM samples [21]. Expressions of leukemia-
associated genes, including Wilms’ tumor gene 1 (WT1) and RUNX1/
RUNX1T1, were evaluated by TaqMan-based reverse-transcription poly-
merase chain reaction (RT-PCR) of diagnostic specimens. PCR-positivity was
deﬁned as an RUNX1/RUNX1T1 transcript level >0.10% or a WT1 transcript
level >0.60% [15].
Routine MRD monitoring was performed at 1, 2, 3, 4.5, 6, 9, and 12
months post-transplantation and at 6-month intervals thereafter. The tests
were repeated 2 weeks after positive FCM or PCR results were detected.
MRD-positive status was deﬁned as FCM positivity in 2 consecutive BM
samples within a 2-week interval, PCR positivity in 2 consecutive BM
samples within a 2-week interval, or both FCM and PCR positivity in a single
BM sample [22]. MRD status was also monitored at 1, 2, 3, 4.5, 6, 9, and 12
months postintervention and at 6-month intervals thereafter.
Preemptive Intervention after Detection of MRD
Post-transplantation immunosuppressionwas immediately tapered and
discontinued in subjects who were MRD-positive at 100 days afteratient who underwent only tapering immunosuppressive therapy (IST) was
Table 1
Patient Characteristics
Characteristic DLI Group (n ¼ 45) IFN-a Group (n ¼ 22) P Value
Age at HSCT, yr, median (range) 24 (2-58) 28 (5-51) .873
Time from HSCT to MRDþ, d, median (range) 166 (55-497) 172 (90-576) .759
Time from HSCT to intervention, d, median (range) 194 (79-520) 182 (90-582) .378
Late-onset MRD, n (%) 36 (80.0) 17 (77.3) 1.000
Diagnosis, n (%) .716
AML 25 (55.6) 11 (50.0)
Acute lymphoblastic leukemia 15 (33.3) 7 (31.8)
Myelodysplastic syndrome 5 (11.1) 4 (18.2)
Disease risk at diagnosis, n (%) .485
Low risk 8 (17.8) 5 (22.7)
Intermediate risk 30 (66.7) 16 (72.7)
High risk 7 (15.5) 1 (4.6)
Sex, n (%) .092
Male 23 (51.1) 16 (72.7)
Female 22 (48.9) 6 (27.3)
Disease status at transplantation, n (%) d
CR1 35 (77.8) 18 (81.8)
CR2 5 (11.1) 0 (0.0)
RAEB1 2 (4.4) 3 (13.6)
RAEB2 3 (6.7) 1 (4.6)
Donor-recipient sex match, n (%) .557
Male-male 15 (33.3) 9 (40.9)
Male-female 16 (35.6) 6 (27.3)
Female-male 8 (17.8) 6 (27.3)
Female-female 6 (13.3) 1 (4.5)
Donor-recipient relationship, n (%) 1.000
Father-child 15 (33.3) 8 (36.4)
Mother-child 4 (8.9) 2 (9.1)
Sibling-sibling 23 (51.1) 11 (50.0)
Child-parent 3 (6.7) 1 (4.5)
Donor type .667
HLA-identical sibling donor 14 (31.1) 8 (36.4)
HLA-haploidentical related donor 31 (68.9) 14 (63.6)
HLA-A, -B, or -DR mismatches, n (%) .279
0 14 (31.1) 8 (36.4)
1 1 (2.3) 3 (13.6)
2 6 (13.3) 2 (9.1)
3 24 (53.3) 9 (40.9)
ABO match, n (%) .866
Matched 25 (55.6) 12 (54.5)
Major mismatched 7 (15.6) 2 (9.1)
Minor mismatched 10 (22.2) 6 (27.3)
Major-minor mismatched 3 (6.6) 2 (9.1)
HCT-CI before HSCT, n (%) .236
0 35 (77.8) 20 (91.0)
1-2 9 (20.0) 1 (4.5)
3 1 (2.2) 1 (4.5)
MRD before preemptive intervention, n (%)* .278
Leukemia-associated genes positive 22 (48.9) 16 (72.7)
WT1 positive 18 (40.0) 13 (59.1)
RUNX1/RUNX1T1 positive 4 (8.9) 3 (13.6)
FCM positive 3 (6.7) 2 (9.1)
Leukemia-associated genes and FCM positive 20 (44.4) 4 (18.2)
WT1 positive and FCM positive 17 (37.8) 3 (13.6)
RUNX1/RUNX1T1 positive and FCM positive 3 (6.6) 1 (4.6)
GVHD prophylaxis, n (%)
CSA 43 (95.6) d
MTX 2 (4.4)
Receipt of second DLI for MRDþ at 1 month, n (%) 4 (8.9) d
Acute GVHD after preemptive intervention, n (%) 1.000
None 39 (86.7) 19 (86.4)
Grade I 0 (0.0) 1 (4.5)
Grade II-IV 6 (13.3) 2 (9.1)
Chronic GVHD after preemptive intervention, n (%) .029
None 18 (40.0) 2 (9.1)
Mild to moderate 10 (22.2) 9 (40.9)
Severe 17 (37.8) 11 (50.0)
Relapse, n (%) 18 (40.0) 7 (31.8) .516
NRM, n (%) 2 (4.4) 1 (4.5) 1.000
DFS, n (%) 25 (55.6) 14 (63.6) .529
GRFS, n (%) 5 (11.1) 1 (4.5) .655
Duration of follow-up, d, median (range) 528 (178-1410) 567 (248-1180) .292
RAEB indicates refractory anemia with excess blasts.
Statistical signiﬁcance was set at P < .05.
* MRD-positive status was deﬁned as FCM positivity in 2 consecutive BM samples within a 2-week interval, PCR positivity in 2 consecutive BM samples within
a 2-week interval, or both FCM and PCR positivity in a single BM sample.
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subjects who were MRD-positive at >100 days after transplantation.
Preemptive IFN-a
Recombinant human IFN-a-2b injections (Anferon; Tianjin Hualida
Biotechnology, Tianjin, China) were administered s.c. at a dosage of 3 million
units 2e3 times per week, for a maximum of 6 months. Patients with active
acute GVHD (aGVHD), active cGVHD, active infections, severe myelosup-
pression (white blood cell count <1.0  109 cells/L, absolute neutrophil
count [ANC] <0.5  109 cells/L, hemoglobin count <65 g/L, or platelet count
<25  109 cells/L), organ failure, or relapse were excluded from IFN-a
treatment. Patients with increasing MRD after preemptive IFN-a treatment
were eligible for DLI. Only patients with grade II-IV aGVHD or moderate to
severe cGVHD received immunosuppressive therapy after IFN-a treatment.
Preemptive DLI
Patients with active aGVHD, active cGVHD, active infection, or organ
failure were excluded from DLI treatment. The protocol for DLI has been
described detail by Yan et al. [7]. G-CSFemobilized peripheral blood stem
cells were administered instead of the more common unstimulated donor
blood lymphocytes. The median doses of mononuclear cells, CD3þ cells,
CD4þ lymphocytes, CD8þ lymphocytes, and CD34þ cells were 1.0 (range, 0.9
to 1.5)  108/kg, 3.4 (range, 1.8 to 7.4)  107/kg, 1.9 (range, 1.1 to 4.4)  107/
kg, 1.2 (range, 0.5 to 2.8)  107/kg, and 0.3 (range, 0.1 to 1.2)  106/kg,
respectively. These median cell doses for infusion were comparable in the
haplo-RD and ISD groups (Supplementary Table 1).
Patients also received antileukemic chemotherapy at 48 to 72 hours
before DLI. Chemotherapy regimens included HAA (harringtonine 2
mg$m2$day1 for 5 days, aclacinomycin 10 mg$m2$day1 for 5 days, and
Ara-C 100 mg$m2$day1 for 5 days), AA (aclacinomycin 10 mg$m2$day1
for 5 days and Ara-C 100 mg$m2$day1 for 5 days), or HA (harringtonine 2
mg$m2$day1 for 5 days and Ara-C 100 mg$m2$day1 for 5 days) in pa-
tients with AML or myelodysplastic syndrome,; and MTX (1.0 g$m2$day1
for 1 day) or CODP (cyclophosphamide 800 mg$m2$day1 for 2 days,
vincristine 1 mg$m2$day1 for 1 day, daunorubicin 40 mg$m2$day1 for 3
days, and prednisone 60 mg$day1 for 7 days) in patients with acute
lymphoblastic leukemia.
In patients who were MRD-positive at 1 month after DLI, salvage DLI
with previous chemotherapy was administered at 3 or 6 months after the
ﬁrst DLI for those without or with GVHD, respectively. The cell doses for
infusion in the subsequent DLI were comparable to those administered in
the ﬁrst DLI (data not shown). Patients received immunosuppressive drugs,
such as CSA or MTX, to prevent GVHD after DLI. Patients receiving DLI from
an ISD received GVHD prophylaxis for 4 to 6 weeks, and those receiving DLI
from a haplo-RD received GVHD prophylaxis for 6 to 8 weeks at the
discretion of the attending physician (and usually depending on the pa-
tient’s GVHD status after DLI). The starting dosage of CSA was 2.5
mg$kg1$day1, which was adjusted to maintain a plasma concentration
150-250 ng/mL. MTX was administered at 10 mg i.v. on days 1, 4, 8, and
weekly thereafter for 2 to 6 weeks.
Treatment of GVHD after preemptive intervention
When GVHD (grade II-IV aGVHD or moderate to severe cGVHD)
occurred after IFN-a or after DLI when immunosuppressive agents had
already been discontinued, CSA was administered as soon as possible and
then adjusted to maintain a blood concentration >150 ng/mL. If GVHD was
not controlled by CSA, then primary therapy, including methylprednisolone
(MP) and MTX, was administered alone or in combination. MP was
administered i.v. at a dose of 1 to 2mg$kg1$d1 for at least 3 days; MTXwas
administered at a dose of 5 or 10 mg on days 1, 4, and 8 and weekly
thereafter. If there was no response or an inadequate response to primary
therapy, then second-line therapy, such as an anti-CD25 monoclonal anti-
body (Basiliximab; Novartis, Basel, Switzerland), was administered at a dose
of 20 mg on days 1, 3, and 8 and weekly thereafter, until the patient
exhibited complete response or treatment failure [23,24].
Deﬁnitions and Assessments
The disease risk of diagnosis was reported according to the criteria of
Armand et al. [25] (Supplementary Table 2). Adverse events after preemp-
tive interventionwere scored using the National Cancer Institute’s Common
Toxicity Criteria version 4.0, and GVHD was excluded as an adverse event.
GVHD occurring after preemptive intervention was diagnosed according to
accepted international criteria [26,27]. Clinical manifestations, and not the
time to symptomatic onset after intervention, determine whether the
clinical syndrome of GVHD is considered acute or chronic [27]. Relapse was
deﬁned as morphological evidence of disease in samples from the periph-
eral blood, BM, or extramedullary sites or by the recurrence and sustained
presence of pretransplantation chromosomal abnormalities. Patients who
exhibited MRD were not classiﬁed as having relapsed. Nonrelapse mortality(NRM) was deﬁned as death after HSCT without disease progression or
relapse. Disease-free survival (DFS) was deﬁned as the survival period with
continuous CR. GVHD-free/relapse-free survival (GRFS) events were deﬁned
as grade III-IV aGVHD, cGVHD requiring systemic immunosuppressive
treatment, disease relapse, or death from any cause after preemptive
intervention [28]. Performance status after preemptive intervention was
evaluated according to the Karnofsky score, which was recorded at the last
follow-up. Early-onset MRD (EMRD) was deﬁned as MRD positivity at 100
days after HSCT, and late-onset MRD (LMRD) was deﬁned as MRD positivity
at >100 days after HSCT.
Statistical Analysis
Data were censored at the time of relapse, nonrelapse mortality (NRM),
or last available follow-up. Continuous variables were compared using the
Mann-Whitney U test, and categorical variables were compared using the
chi-squared and Fisher exact tests. Clinical outcomes were compared be-
tween the DLI and IFN-a group, and also among MRD-positive patients with
preemptive intervention, MRD-positive patients without preemptive
interventions in the present cohort (n ¼ 26), and MRD-positive patients
without intervention in the historical cohort (n ¼ 14). The Kaplan-Meier
method was used to estimate the probabilities of DFS and GRFS. For DFS,
relapse or death (ie, treatment failure as deﬁned by DFS) was considered an
event, and data on patients who were alive and in continuous CR were
censored at the last follow-up. For GRFS, GVHD (grade III-IV aGVHD or
cGVHD requiring systemic immunosuppressive treatment), relapse, or death
(ie, treatment failure as deﬁned by GRFS) was considered an event, and data
on patients who were alive without GVHD and in continuous CR were
censored at the last follow-up. Cumulative incidences were estimated for
NRM and relapse to accommodate for competing risks. Relapse was the
competing event for NRM and vice versa [29].
A landmark analysis was performed to assess the effects of preemptive
IFN-a and DLI on each outcome. The post-transplantation day of interven-
tion was deﬁned as the landmark day. Relapse was calculated from the
landmark day to relapse. NRMwas calculated from the landmark day to date
of death after HSCT without disease progression or relapse. DFS was
calculated from the landmark day to relapse, death from any cause, or date
of last contact. GRFS was calculated from the landmark day to date of the
ﬁrst event.
Potential prognostic factors for 1-year clinical outcomes after interven-
tion were evaluated by multivariate analysis using Cox proportional hazards
regression with a backward-stepwise model selection approach. Factors
included in the regression model for relapse, NRM, and DFS were sex, disease
risk at diagnosis (high risk versus intermediate risk versus low risk), HLA
disparity (ISD versus haplo-RD), type of preemptive treatment (IFN-a versus
DLI), time from HSCT to MRD (EMRD versus LMRD), MRD status after pre-
emptive intervention, and cGVHD after preemptive intervention (negative
versus mild-to-moderate versus severe cGVHD). All of the aforementioned
factors except cGVHD were included in the regression model for GRFS.
Independent variables showing P > .10 were sequentially excluded from
the model, and the level of signiﬁcance was set at P < .05. All reported P
values were based on 2-sided tests. Data analyses were conducted primarily
with SPSS software (SPSS Inc., Chicago, IL), with the R version 2.6.1 (http://
www.r-project.org) used for competing risk analysis.
RESULTS
Clinical Outcomes of MRD-Positive Patients with and
without Preemptive Intervention
The 2-year cumulative incidences of relapse and DFS after
HSCT were 30.2% and 43.9% (P ¼ .480) and 64.2% and 53.8%
(P ¼ .620), respectively, in the preemptive IFN-a and DLI
groups. Both of these incidences were signiﬁcantly better
than those of the MRD-positive patients without preemptive
interventions in the present cohort (n ¼ 26; 2-year relapse,
56.5%; 2-year DFS, 33.0%). The 2-year cumulative incidence
of NRM after HSCT was comparable in the MRD-positive
patients with and without preemptive interventions in the
present cohort (Figure 2A-C). Data for MRD-positive patients
receiving preemptive intervention in the present cohort and
MRD-positive patients without intervention in the historical
cohort (n¼ 14) are compared in Supplementary Figure 1A-C.
Duration of Preemptive IFN-a
Themedian duration of IFN-a therapy was 35 days (range,
4 to 180 days). One patient received IFN-a treatment for 6
Figure 2. Clinical outcomes according to MRD status and preemptive interventions after HSCT. (A) Cumulative incidence of relapse at 2 years after HSCT: MRD-
negative versus MRD-positive without intervention, P < .001; preemptive DLI versus MRD-positive without intervention, P ¼ .018; preemptive IFN-a versus MRD-
positive without intervention, P ¼ .027. (B) Cumulative incidence of NRM at 2 years after HSCT: MRD-negative versus MRD-positive without intervention, P ¼
.481; preemptive DLI versus MRD-positive without intervention, P ¼ .069; preemptive IFN-a versus MRD-positive without intervention, P ¼ .342. (C) Probability of
DFS at 2 years after HSCT: MRD-negative versus MRD-positive without intervention, P < .001; preemptive DLI versus MRD-positive without intervention, P ¼ .004;
preemptive IFN-a versus MRD-positive without intervention, P ¼ .016. The red line represents the MRD-negative group (n ¼ 365); the blue line, the preemptive DLI
group (n ¼ 45); the gray line, the preemptive IFN-a group (n ¼ 22); the green line, the MRD-positive without intervention group (n ¼ 26). The patient who received
only tapering IST was included in the MRD-positive without intervention group.
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because of grade III-IV aGVHD (n ¼ 1) or moderate to severe
cGVHD (n ¼ 18); in these patients, the median duration of
IFN-a therapy was 26 days (range, 4 to 106 days). Two pa-
tients discontinued IFN-a treatment at 19 days and 26 days
after intervention because of relapse.Adverse Events of Preemptive Interventions
The adverse events associated with preemptive inter-
vention were summarized in Supplementary Table 3. In the
IFN-a group, 20 patients reported transient fever; however,
the maximum temperature did not exceed 39C, and fever
resolved spontaneously in all cases. None of the patients
suffered severe hematology toxicity. In the DLI group, 36
patients experienced aplasia, with a median duration of 12
days (range, 6 to 29 days). Twenty-eight patients sustained
infection after DLI, 2 of whom with Escherichia coli septic
shock.Figure 3. Cumulative incidence of cGVHD at 1 year after preemptive IFN-a and
DLI treatments (P < .001). The red solid line represents the DLI group (n ¼ 45);
the blue dashed line, the IFN-a group (n ¼ 22).GVHD
Three patients developed aGVHD after preemptive IFN-a
(1 each with grade I, II, and IV aGVHD). Six patients devel-
oped aGVHD after preemptive DLI (3 with grade II, 2 with
grade III, and 1 with grade IV) (Table 1). The median time
from intervention to occurrence of aGVHD was 13 days
(range, 2 to 17 days) in the IFN-a group and 44 days (range,15
to 61 days) in the DLI group (P ¼ .048).
In the IFN-a group, 20 patients experienced cGVHD,
including 1 patient with mild cGVHD, 8 patients with mod-
erate cGVHD, and 11 patients with severe cGVHD (Table 1).
The rate of cGVHD was comparable between the haplo-RD
and ISD groups (85.7% versus 100%; P ¼ .515). In the DLI
group, 27 patients experienced cGVHD, including 2withmild
cGVHD, 8 with moderate cGVHD, and 17 with severe cGVHD
(Table 1). The rate of cGVHD was higher in the haplo-RD
group compared with the ISD group (71.0% versus 35.7%;
P¼ .025). Themedian time from intervention to occurrence of
cGVHD was 36 days (range, 7 to 171 days) in the IFN-a group
and 72 days (range, 32 to 148 days) in theDLI group (P¼ .022).Among the patients with cGVHD, 19 patients in the IFN-a
group and 25 patients in the DLI group received systemic
immunosuppressive therapy. The 1-year cumulative inci-
dence of cGVHD after preemptive intervention was 90.9% in
the IFN-a group and 62.9% in the DLI group (P < .001;
Figure 3), and the 1-year cumulative incidence of mild to
moderate cGVHD and severe cGVHD was 40.9% versus 23.4%
(P ¼ 0.118) and 50.0% versus 39.5% (P ¼ 0.248) for patients
who received IFN-a versus DLI treatment, respectively.MRD Status and Relapse after Intervention
The clinical outcomes were comparable among the pa-
tients in the 3 MRD status groups before the preemptive
interventions (Supplementary Figure 2A and B). Two pa-
tients relapsed within 1 month after receiving IFN-a. One
patient died from severe pneumonia within 1 month after
X.-D. Mo et al. / Biol Blood Marrow Transplant 21 (2015) 1939e19471944receiving DLI, and 3 patients relapsed within 1 month after
receiving DLI. These 6 patients were excluded from our
analysis. A total of 61 patients (IFN-a, n ¼ 20; DLI, n ¼ 41)
were enrolled in the analyses of MRD status after preemptive
interventions and outcomes.
Eighteen patients (90.0%) turned MRD-negative after
receiving IFN-a, including 11 (55.0%) at 1 month, 3 (15.0%) at
2 months, 2 (10.0%) at 3 months, and 2 (10.0%) at >3 months
after preemptive IFN-a. Ten patients discontinued IFN-a
treatment before becoming MRD-negative because of active
GVHD; in these patients, the median time from IFN-a
cessation to MRD-negative status was 23 days (range, 4 to 34
days). Eight patients continued IFN-a after turning MRD-
negative; in these patients, the median time from
MRD-negative status to IFN-a cessation was 117 days (range,
35 to 151 days). Twenty-nine patients (70.7%) turned
MRD-negative after DLI, including 16 (39.0%) at 1 month, 7
(17.1%) at 2 months, 3 (7.3%) at 3 months, and 3 (7.3%) at >3
months after preemptive DLI.
Two patients (10%) did not turn MRD-negative after
IFN-a; 1 of these patients (5%) died from severe pneumonia
before becoming MRD-negative, and the other (5%)
continued IFN-a treatment but relapsed 2 months after the
intervention. Twelve patients (29.3%) did not achieve
MRD-negative status after DLI. Two of these patients
received salvage DLI treatment at 3 months after the ﬁrst
DLI, and the other patients did not receive additional DLI
treatments because of active GVHD. Ten patients (24.4%)
patients relapsed, including 3 (7.3%) who relapsed within 2
months after DLI, 5 (12.2%) who relapsed within 3 months
after DLI, and 2 (4.9%) who relapsed more than 3 months
after DLI.
Five patients who achieved MRD-negative status after
preemptive IFN-a turned MRD-positive again. One of these
patients received IFN-a again, and the other 4 patients did
not receive further intervention because of active GVHD. Two
patients (40%) turned MRD-negative again, and both ach-
ieved continued CR; 1 patient with persistent MRD relapsed.
Seven patients who achieved MRD-negative status after
preemptive DLI turned MRD-positive again. Two received a
second DLI treatment, 1 received chemotherapy, and 4 pa-
tients did not receive any further intervention because of
active GVHD. Two (28.6%) turned MRD negative again and allFigure 4. Cumulative incidence of relapse (A; P ¼ .514) and NRM (B; P ¼ .985) at 1 year
group (n ¼ 45); the blue dashed line, the IFN-a group (n ¼ 22).achieved continued CR, and 3 patients with persistent MRD
relapsed.
Seven patients relapsed after preemptive IFN-a, and 18
patients did so after preemptive DLI. The median time from
intervention to relapse was 136 days (range, 19 to 536 days)
in the former group and 90 days (range, 24 to 598 days) in
the latter group (P ¼ .423). The cumulative incidence of
relapse at 1 year after preemptive intervention was 27.3% in
the IFN-a group and 35.6% in the DLI group (P ¼ .514;
Figure 4A). In multivariate analysis, persistent MRD after
intervention was signiﬁcantly associated with increased risk
of relapse (Table 2).NRM
One patient died from severe pneumonia at 131 days after
receiving IFN-a; 2 patients died from severe pneumonia and
GVHD at 20 days and 143 days, respectively, after receiving
DLI. The cumulative incidence of NRM at 1 year after pre-
emptive interventionwas 4.5% in the IFN-a group and 4.4% in
the DLI group (P ¼ .985; Figure 4B). In multivariate analysis,
none of variables was signiﬁcantly associated with increased
NRM, and IFN-a recipients did not show increased risk of
NRM compared with DLI recipients (hazard ratio, 0.99; 95%
CI, 0.09 to 10.94; P ¼ .995).DFS, Performance Status after Intervention, and GRFS
The probabilities of DFS at 1 year after preemptive inter-
vention were 68.2% in the IFN-a group and 60.0% in the DLI
group (P ¼ .517; Figure 5A). In multivariate analysis, persis-
tent MRD and non-cGVHD after preemptive intervention
were signiﬁcantly associated with poorer DFS.
Themedian Karnofsky scorewas 70 (range, 50 to 90) in the
IFN-a group and70 (range, 20 to 90) in theDLI group (P¼ .100).
The median score was 80 (range, 20 to 90) in patients without
cGVHDand 75 (range, 60 to 90) in thosewithmild tomoderate
cGVHD (P ¼ .283), both signiﬁcantly higher than the median
score inpatientswith severe cGVHD (60; range, 40 to 80) (non-
cGVHD versus severe cGVHD, P < .001; mild to moderate
cGVHDversus severe cGVHD,P¼ .002). TheprobabilityofGRFS
at 1 year after preemptive intervention was 4.5% in the IFN-a
groupand7.2% in theDLI group (P¼ .030; Figure5B), andEMRD
was associated with poorer GRFS (Table 2).after preemptive IFN-a and DLI treatments. The red solid line represents the DLI
Table 2
Multivariate Analysis of Prognostic Factors for 1-Year Clinical Outcomes in Patients after Preemptive Interventions
Variable Relapse Treatment Failure as Deﬁned
by DFS
Treatment Failure as Deﬁned
by GRFS
HR 95% CI P HR 95% CI P HR 95% CI P
Sex
Male 1.00 .705 1.00 .316 1.00 .861
Female 1.22 0.43-3.48 1.65 0.62-4.42 1.05 0.60-1.85
Disease risk at diagnosis
Low risk 1.00 1.00 1.00
Intermediate risk 1.31 0.45-3.86 .622 2.27 0.79-6.58 .130 1.49 0.68-3.28 .321
High risk 0.77 0.14-4.24 .768 3.42 0.68-17.19 .136 0.79 0.26-2.46 .681
Donor type
ISD 1.00 .600 1.00 .262 1.00 .569
Haplo-RD 0.76 0.27-2.14 0.59 0.24-1.48 1.20 0.64-2.23
Type of preemptive intervention
DLI 1.00 .518 1.00 .609 1.00 .093
IFN-a 0.64 0.16-2.52 1.32 0.45-3.84 1.66 0.92-3.01
MRD status postintervention
Persistent MRD after intervention 1.00 1.00 1.00
MRD-negative 1 mo after intervention 0.08 0.03-0.25 <.001 0.08 0.03-0.26 <.001 0.97 0.51-1.87 .937
MRD-negative beyond 1 mo after intervention 0.03 0.01-0.25 .001 0.07 0.02-0.32 .001 0.63 0.31-1.28 .197
Time from HSCT to MRD-positive status
EMRD 1.00 .171 1.00 .053 1.00 .041
LMRD 0.45 0.15-1.41 0.35 0.12-1.01 0.53 0.29-0.97
Chronic GVHD after intervention d
None 1.00 1.00
Mild to moderate 0.49 0.17-1.45 .199 0.25 0.07-0.87 .030
Severe 0.54 0.21-1.44 .219 0.56 0.22-1.39 .211
HR indicates hazard ratio.
Bold type indicates statistical signiﬁcance (P < .05).
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Although preemptive DLI based on MRD status can
signiﬁcantly improve the clinical outcomes of patients after
HSCT [6,7], some patients cannot receive preemptive DLI
after HSCT because of either provider refusal or patient
refusal. In the present study, we observed a 1-year cumula-
tive incidence of relapse and DFS after intervention of 35.6%
and 60.0%, respectively, in patients receiving preemptive DLI.
Patients receiving preemptive IFN-a had similar clinical
outcomes as the DLI recipients, suggesting that IFN-amay be
a potential alternative for MRD-positive patients who refuse
or are unable to receive preemptive DLI.Figure 5. Probability of DFS (A; P ¼ .517) and GRFS (B; P ¼ .030) at 1 year after preem
45); the blue dashed line, the IFN-a group (n ¼ 22).Our previous study reported a relapse rate exceeding 70%
in patients who were MRD-positive after HSCT but not
receiving any interventions [15]; the 2-year relapse rate of
only 30.2% in the present study suggests that preemptive
IFN-a is effective for MRD-positive patients. IFN-amay exert
an immunomodulatory effect in HSCT recipients, which can
promote the GVL effect and further clear tumor cells [8,9].
We also observed that even though IFN-a treatment was
discontinued in 10 of the IFN-a recipients because of active
GVHD, MRD remained signiﬁcantly decreased and MRD-
negative status was achieved, indicating that IFN-a indeed
might promote the GVL effect and clear tumor cells. In
addition, because chemotherapy and immunosuppressiveptive IFN-a and DLI treatments. The red solid line represents the DLI group (n ¼
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the present study IFN-a was administered without chemo-
therapy and immunosuppressive agents to maximize the
GVL effect. On the other hand, in vivo and in vitro studies
have found that IFN-a can dramatically inhibit the prolifer-
ation of acute leukemia cells [30-32]. Thus, IFN-a may clear
MRD through different mechanisms. Similarly, Klingemann
et al. [33] reported that 9 of 14 high-risk patients with re-
fractory/relapsed hematologic malignances who received
preemptive IFN-a after HSCT achieved continued CR.
In thepresent study,we foundahigher incidence of cGVHD
and shorter median time from intervention to occurrence of
cGVHD in the IFN-a group compared with the DLI group.
Several previous studies have observed that cGVHD is closely
related to the GVL effect [34,35]. It is possible that IFN-amay
rapidly induce the GVL effect and clear theMRD.We observed
that 55.0% of the IFN-a recipients and 39.0% of the DLI re-
cipients achieved MRD-negative status by 1 month after
intervention, a key factor in reducing relapse and improving
DFS in ourmultivariate analysis. Thismay partially account for
the fact that IFN-a recipients can achieve similar relapse and
DFS rates as DLI recipients. Some authors have reported that
cGVHD might have an adverse effect on NRM after myeloa-
blative conditioning HSCT [36]; however, Arai et al. [37] re-
ported signiﬁcantly higher NRM in patients with severe
cGVHD compared with those with mild or moderate cGVHD.
In the present study, the incidence of severe cGVHD was
comparable in the IFN-a and DLI groups. In addition, several
previous studies found that even severe cGVHD was not
associatedwith an increased risk of NRM [38,39]. On the other
hand, PUIH is the largest HSCT center in China, performing
more than 1000 HSCTs to date. We have extensive experience
in treating cGVHD, particularly severe cGVHD, and have found
thatmanypatientswith cGVHDcan avoidNRM. In our present
cohort, despite the high incidence of cGVHD, the presence of
cGVHD did not signiﬁcantly increase the risk of NRM in the
IFN-a group compared with the DLI group; however, severe
cGVHD did not signiﬁcantly improve DFS in our multivariate
analysis, and the performance status of these patients was
poor. Previous studies also have reported signiﬁcantly
impaired quality of life in patients with severe cGVHD [40,41].
Given the 50% incidence rate of severe cGVHD in the present
study, controlling cGVHD severity after IFN-a is important for
further improvement of this preemptive intervention.
In the present study, the 1-year NRM after intervention
was 4.5% in the IFN-a group, and most patients experienced
only transient fever during therapy. No severe myelotoxicity
was observed, and only 1 patient had a fatal infection. In the
study reported by Klingemann et al. [33], it was necessary to
reduce the dose of IFN-a by 25% in only 1 patient because of
grade 2 nausea, vomiting, and anorexia. No life-threatening
complications were seen and all side effects were reversed,
usually within 1 week after discontinuation of IFN-a. These
observations suggest that IFN-a may be a safe preemptive
intervention for MRD-positive patients after HSCT. In addi-
tion, we found a comparable incidence of NRM in the IFN-a
and DLI groups.
Along with the comparable incidence of severe cGVHD
after intervention described above, the similar incidences of
NRM also may be related to comparable rates of severe
aGVHD after intervention. Severe aGVHD is one of the most
signiﬁcant causes of NRM after post-HSCT immunotherapy.
In the present study, the ratio of patients with grade II to IV
aGVHD was 9.1% in IFN-a group, comparable to the 13.3% in
the DLI group. Finally, pre-HSCT comorbidities stronglypredict NRM after HSCT [19,42]; however, the proportion of
patients with an HCT-CI score of 3 was comparable in the
IFN-a and DLI groups, suggesting comparable pre-HSCT co-
morbidity burden in the 2 groups.
GRFS, a composite endpoint, represents ideal recovery
fromHSCTand ameasure of curewithout ongoingmorbidity.
The probability of GRFS at 1 year after preemptive inter-
vention was only 4.5% in the IFN-a group and 7.2% in the DLI
group; however, inducing a GVL effect was one of the most
important objectives of preemptive immunotherapy in pa-
tients whowere MRD-positive after HSCT, and GVHDmay be
inevitable. Thus, the improved DFS after preemptive IFN-a or
DLI may come at the cost of impaired quality of life. New
preemptive interventions that can enhance the GVL effect
while decreasing the toxicity of GVHD may further improve
the GRFS.
This study has several limitations. First, the number of
patients receiving preemptive IFN-a was somewhat small,
which could have inﬂuenced the accuracy of our ﬁndings.
Second, the relatively short observation period hindered the
evaluation of long-term relapse after IFN-a treatment. Third,
more than 75% of patients in our cohort had LMRD, and thus
the efﬁcacy of preemptive IFN-a in EMRD patients requires
further investigation. Fourth, one-half of our MRD-positive
patients could not receive preemptive intervention because
of active GVHD, and the GVL effect might clear the MRD;
thus, our data might not fully reﬂect the clinical outcomes of
MRD-positive patients without intervention. This also may
account for the better clinical outcomes of our MRD-positive
patients without intervention compared with the historical
cohort. Finally, patients with acute leukemia in nonremission
before HSCT routinely received prophylactic DLI after HSCT,
and patients with a t(9;22) mutation routinely received
prophylactic or preemptive imatinib after HSCT; thus, these
patients were not enrolled in the preemptive DLI or IFN-a
treatment in the present study. Because patients with
advanced-stage acute leukemia compose approximately 25%
of the patients with acute leukemia receiving HSCT at PUIH
[17], the number of patients with poor-risk cytogenetics was
relatively small in the present study. The efﬁcacy of pre-
emptive IFN-a treatment in patients with poor-risk cytoge-
netics merits further study.
In summary, preemptive IFN-a may be safe and effective
for MRD-positive patients and may provide a potential
alternative for patients unable to receive preemptive DLI
after HSCT. The efﬁcacy of IFN-a should be further conﬁrmed
in large-scale, prospective clinical studies.ACKNOWLEDGMENTS
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